摘要
用125Ⅰ标记单抗MC5对载人直肠癌裸且进行实验性治疗研究。125Ⅰ--MC5对体外直肠癌细胞的特异性结合率为0.444。每只小鼠腹腔注射单次剂量7.5MBq的125Ⅰ--MC5发现在49d后有促进肿瘤生长作用。平均瘤重增加1.5996±0.40998。对照组为0.6646±0.3266g,但两组比较没有统计学上差异(P<0.2)。3H--TdR掺入肿瘤细胞的量检测,125Ⅰ--MC5组为15530.4±1327.6dpm/g,对照组为8608.5±1255.2dpm/g。两组比较有非常显著差异(P<0.01)。实验结果提示:抗结肠癌单抗MC5可以用作人肠癌的导向治疗。但125Ⅰ不是一个好的导向治疗标记同位素。低剂量幅射可能促进肿瘤生长。
A study on human rectal adenocarcinoma xenograft in nude mice treated by 125I labeled MC5 monoclonal antibody is reported.The specific binding rate of the 125I-MC5 to rectal cancer cells in vitro was 0.444.Each animal received(i.p)a single dose of 7. 5 MBq. It was found that 125I-MC5 was able to stimulate tumor groWth and the tumor mean weight increased 1. 5996±0.40999 at the 49th day after injection.While in the control group the mean weight in creased 0. 6646 ±0. 3266g, but the difference was not statistically significant (p>0.05).The amounts of 3H-TdR incorporation in experimental group and control group were 15530.4 ± 1327.6 Dpm/g and 8608.5±1255.2 Dpm/g respectively. The difference was statistically significant(p<0.01).The result suggests that McAb MC5 may be used in targeting therapy of human rectal cancer but 125I isn't a good labeled isotope in the targeting therapy.The low dose radiation may stimulates tumor growth.
基金
浙江省自然科学基金
关键词
单克隆抗体
碘125
标记
癌
肠肿瘤
monoclonal antibody MC5
125I-labeled
rectal carcinoma
nude mice
experimental therapy